welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Open Label Extension Study of HT-100 in Patients With DMD

key information

study id #: NCT01978366

condition: Duchenne Muscular Dystrophy

status: terminated


This study is designed to provide 6-months continuous dosing with the study medication, called HT-100, on participants who successfully completed the predecessor study (HALO-DMD-01). The main purpose of this study is to assess chronic safety, tolerability, pharmacodynamic activity (testing the drug’s effect on DMD) and population pharmacokinetics (measuring how much drug is in the bloodstream) in participants with a broad spectrum of Duchenne muscular dystrophy (DMD).

intervention: HT-100

mechanism of action: Small molecule designed to reduce fibrosis and inflammation

results: https://clinicaltrials.gov/ct2/show/results/NCT01978366

last updated: September 08, 2020